Association of hemoglobin levels in the first trimester and at 26 to 30 weeks with fetal and neonatal outcomes: A secondary analyses of the Global Network for Women’s and Children’s Health’s ASPIRIN Trial
BJOG: An International Journal of Obstetrics and Gynaecology Mar 03, 2021
Jessani S, Saleem S, Hoffman MK, et al. - Since there is minimal evidence from low‐ and middle‐income countries on the association of hemoglobin (HGB) levels at different times in pregnancy to adverse outcomes, researchers sought to assess the correlation of HGB levels in nulliparous women at two times in pregnancy with pregnancy outcome. They used ASPIRIN Trial data to study the link between HGB levels measured at 6 +0 to 13 +6 weeks and 26 +0 to 30 +0 weeks gestational age (GA) with fetal and neonatal outcomes. The sample consisted of 11,976 pregnant women. Both lower and some higher HGB concentrations are related to adverse fetal and neonatal outcomes at 6 +0–13 +6 weeks and at 26–30 weeks GA, though the correlation with low HGB levels seems more consistent and generally stronger.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries